Lactobacillus acidophilus to inhibit cryptosporidiosis in mammals
US5858356A · kind A · utility
85Cited by
4References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 21, 1995 |
| Grant date | Jan 12, 1999 |
| Priority date | — |
| Expiry date | Dec 21, 2015 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S435/854
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Cryptosporidium parvum (the cause of cryptosporidiosis) has become one of the most common enteropathogens causing diarrhea worldwide. Symptoms associated with cryptosporidiosis are very debilitating especially in the immunocompromised subject (e.g., AIDS patient). Clinical features include severe, chronic diarrhea, abdominal cramps, fatigue, weight loss, etc. which lead to increased health care costs and increased mortality. There is described herein a method of inhibiting the severity of Cryptosporidium parvum infection by enterally administering a therapeutically effective amount of Lactobacillus acidophilus.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.